Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate High-risk, localized disease that is previously untreated Minimum of 2 positive biopsies Meets at least 1 of the following criteria: Stage T3 Serum PSA greater than 10 ng/mL Gleason score 7-10 Gleason score 6 and at least 3 positive biopsies Potential candidate for radical prostatectomy PATIENT CHARACTERISTICS: Age Over 18 Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic WBC at least 3,000/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 10.0 g/dL Hepatic Bilirubin normal AST and ALT normal PTT normal INR normal Renal Creatinine normal Cardiovascular No significant cardiac dysfunction Other Fertile patients must use effective contraception No known hypersensitivity to oligonucleotides, luteinizing hormone-releasing hormone analogs, or anti-androgens No evidence of active uncontrolled infection No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer No other serious illness, psychiatric disorder, or medical condition that would preclude study compliance No history of a significant neurological disorder that would preclude informed consent No geographical condition that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior chemotherapy for prostate cancer Endocrine therapy No prior hormonal therapy for prostate cancer Radiotherapy No prior radiotherapy for prostate cancer No concurrent radiotherapy Surgery Not specified Other No concurrent heparin or warfarin anticoagulation No other concurrent investigational therapy No other concurrent cytotoxic therapy